meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs Immunostimulant
vs interferon alpha
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
ipilimumab based treatment
ipilimumab alone
nivolumab based treatment
pembrolizumab based treatment
Immune checkpoint association
ipilimumab alone
Ipilimumab (10 mg/kg)
nivolumab alone
pembrolizumab alone
nivolumab plus ipilimumab
mML - NA - all population
9
Comparator:
vs interferon alpha;
vs placebo;
vs Ipilimumab (10 mg/kg);
vs nivolumab alone;
Risk of bias:
low;
some concerns;
high;
NA;